In a recent update, Terry Smith, the founder of Fundsmith Equity, revealed that Novo Nordisk has emerged as the fund's worst-performing investment in 2025. This revelation has raised concerns among investors about the company's market position and future prospects, as The source reports that the stock has faced significant challenges in the current economic climate.
Impact of Wegovy on Fund Performance
Smith pointed out that Novo Nordisk's struggles with its Wegovy weight-loss medication have significantly impacted the fund's overall performance, contributing to a 3 percentage point decline. He expressed disappointment over the company's inability to fend off illegal generic competition, which has undermined its market leadership.
Hope for Recovery Under New Management
Despite these challenges, Smith remains hopeful about Novo Nordisk's potential for recovery under new management. He indicated that if the current issues are addressed effectively, the company could present a promising investment opportunity moving forward.
Novo Nordisk's stock has recently surged following the FDA's approval of its oral Wegovy pill, marking a significant turnaround after its struggles highlighted by Fundsmith Equity's Terry Smith. For more details, see read more.
